Back

Loss of either RASSF1A alone or in combination with Caveolin-1 inhibition is associated with different premalignant histopathological alterations in the mammary glands of transgenic mice

Cotarelo, C. L.; Weber, H. T.; Rosswag, S.; Wagner, T.; Schaefer, I.; Sleeman, J. P.; Thaler, S.

2026-07-15 cancer biology
10.64898/2026.07.14.738049 bioRxiv
Show abstract

Analyses of human breast carcinomas (BCs) and premalignant breast lesions show that the loss of RASSF1A is an early event in the development of ER+ BCs, which correlates linearly with malignant progression. This observation suggests that RASSF1A inhibition is important for the development and progression of ER+ BCs. In addition to RASSF1A, concurrent caveolin-1 (Cav-1) inhibition may further promote ER+ breast carcinogenesis. In the present study, transgenic Rassf1a-/- and Cav-1(-/-) single as well as Rassf1a-/-, Cav-1(-/-) double knockout mice were used to investigate the impact of single or combined Rassf1a and Cav-1 inactivation on BC initiation. Loss of either one or both proteins led to different, pre-malignant histopathological alterations within the mammary glands of the mice, but not to fully developed BC, confirming that Rassf1a and Cav-1 are both important for maintaining the integrity of mammary gland epithelial structure, but suggesting that further intracellular changes or extracellular factors are required for the development of luminal BC when both genes are lost.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 12%
15.3%
2
Breast Cancer Research
36 papers in training set
Top 0.1%
9.8%
3
Cancers
213 papers in training set
Top 0.9%
6.3%
4
BMC Cancer
67 papers in training set
Top 0.2%
6.3%
5
Scientific Reports
3612 papers in training set
Top 12%
6.3%
6
International Journal of Cancer
49 papers in training set
Top 0.2%
4.4%
7
JNCI Cancer Spectrum
10 papers in training set
Top 0.1%
3.3%
50% of probability mass above
8
International Journal of Molecular Sciences
494 papers in training set
Top 3%
3.3%
9
The Journal of Pathology
26 papers in training set
Top 0.2%
2.8%
10
Molecular Oncology
55 papers in training set
Top 0.3%
2.8%
11
npj Breast Cancer
23 papers in training set
Top 0.2%
2.1%
12
Molecular Cancer Research
49 papers in training set
Top 0.5%
2.1%
13
Cell Death Discovery
58 papers in training set
Top 0.5%
1.8%
14
Disease Models & Mechanisms
20 papers in training set
Top 0.1%
1.8%
15
Frontiers in Oncology
103 papers in training set
Top 2%
1.5%
16
Oncotarget
18 papers in training set
Top 0.1%
1.5%
17
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 3%
1.1%
18
Cells
249 papers in training set
Top 4%
1.1%
19
Cell Death & Disease
21 papers in training set
Top 0.3%
1.1%
20
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.1%
21
Cancer Research
130 papers in training set
Top 3%
1.1%
22
eLife
5828 papers in training set
Top 62%
0.9%
23
British Journal of Cancer
49 papers in training set
Top 1%
0.9%
24
Journal of the Endocrine Society
15 papers in training set
Top 0.3%
0.9%
25
Nature Communications
5641 papers in training set
Top 56%
0.9%
26
Oncogene
85 papers in training set
Top 2%
0.9%
27
Science Advances
1243 papers in training set
Top 32%
0.6%
28
Gene
46 papers in training set
Top 2%
0.6%